Eric P. Lefkofsky, who serves as both CEO and Chairman of Tempus AI, Inc. (NASDAQ:TEM), disposed of Class A Common Stock valued at $7,763,312 on May 27, 2026. The disposition involved a total of 166,250 shares, with the weighted average sale prices ranging between $46.17 and $46.89 per share.
The stock currently trades at $50.46, representing a notable gain of 9.3% over the past week. Despite this recent upward momentum, analysis provided by InvestingPro suggests that the company might be trading at an elevated valuation relative to its current levels.
Tempus AI is an artificial intelligence healthcare firm valued at $9.2 billion. The company has demonstrated significant operational strength, posting a 70% revenue growth rate even while navigating ongoing profitability challenges in its sector.
Details of the Share Dispositions
The sales were conducted through several entities managed by Mr. Lefkofsky and were executed pursuant to a Rule 10b5-1 trading plan, which he had previously adopted on March 4, 2025.
Specifically, two entities reported sales: Gray Media, LLC and Blue Media, LLC.
- Gray Media, LLC sold 33,250 shares. This total included 8,932 shares sold at a weighted average price of $46.17 (with individual transaction prices observed between $45.53 and $46.52), and an additional 24,318 shares sold at a weighted average price of $46.89 (with individual transaction prices ranging from $46.53 to $47.47).
- Blue Media, LLC accounted for the remaining sales, disposing of 133,000 shares. This involved 35,721 shares sold at a weighted average price of $46.17 (with individual transaction prices ranging from $45.53 to $46.52), and 97,279 shares sold at a weighted average price of $46.89 (with individual transaction prices ranging from $46.53 to $47.47).
These transactions confirm the utilization of the pre-arranged trading plan for all share dispositions.
Company Progress and Clinical Catalysts
Separately, Tempus AI has reported several major developments concerning its medical technology applications. The company recently presented findings regarding its multimodal foundation models at the 2026 American Society of Clinical Oncology Annual Meeting.
These advanced models are built upon extensive datasets, comprising 2.5 million longitudinal patient records and over 250 million pages derived from clinical notes. Furthermore, Tempus AI achieved a critical regulatory milestone by receiving FDA approval for its xT CDx next-generation sequencing platform, specifically for a tumor-only indication.
This recent FDA companion diagnostic approval is significant because it positions Tempus as the first laboratory to receive such dual approval status: both for comprehensive genomic profiling of tumor-only tissue and tumor-normal tissue. To broaden its market reach, the company also expanded its Next platform, adding six new cancer types to its existing clinical applications.
These collective updates underscore Tempus AI's continuous advancements across the domains of artificial intelligence application within genomics testing and overall medical diagnostics.
Market Analysis Summary
While CEO Lefkofsky sold a substantial block of shares, the company continues to report strong financial metrics. Tempus AI has achieved an impressive 70% revenue growth rate despite facing ongoing challenges related to profitability. However, market analysis cautions that current stock levels may suggest an overvaluation for the firm.
Sector Impact and Key Takeaways
The developments at Tempus AI highlight several key trends impacting the healthcare and biotechnology sectors.
- Genomic Testing and Diagnostics: The FDA approval of the xT CDx platform, particularly for both tumor-only and tumor-normal profiling, solidifies the market's focus on advanced companion diagnostics.
- Artificial Intelligence in Medicine: The presentation of multimodal foundation models based on millions of clinical records emphasizes AI's growing role in interpreting complex medical data and improving diagnostic accuracy.
- Revenue Growth vs. Profitability: Tempus AI's 70% revenue growth demonstrates market adoption, but the mention of ongoing profitability challenges points to sector-wide pressures regarding scaling high-tech healthcare solutions.
Risks and Uncertainties
Several factors mentioned in the reports suggest potential risks or areas requiring continued monitoring:
- Valuation Concerns: Despite strong operational growth, external analysis suggests that Tempus AI's stock may be overvalued at current market levels.
- Profitability Challenges: The company continues to face ongoing challenges regarding profitability, which could impact investor sentiment and financial stability despite high revenue growth.
- Regulatory Dependence: While the FDA approval is a positive catalyst, sustained success relies on continued regulatory acceptance and expanding clinical application of these complex AI-driven diagnostic tools.
Investors seeking deeper insights into TEM's financial health and future prospects are directed to comprehensive research reports covering various US equities.